MRC2 Knockout Firefly Luciferase A549 Cell Line

MRC2 Knockout Firefly Luciferase A549 Cell Line is an A549 lung cancer cell line in which MRC2 (Mannose Receptor C-Type 2) is no longer expressed due to CRISPR/Cas9 genome editing. These cells also constitutively express firefly (Photinus pyralis) luciferase under the control of an EF1a promoter. This cell line was generated by transduction of the MRC2 Knockout A549 Cell Line (BPS Bioscience #83934) with Firefly Luciferase Lentivirus (EF1a Promoter, Hygromycin) (BPS Bioscience #78740-H). This cell line has been validated by genomic sequencing, flow cytometry, and for luciferase activity. MRC2 (Mannose Receptor C-Type 2) is an endocytic recycling receptor that binds collagen and collagen fragments from the extracellular matrix (ECM), targeting them for lysosomal degradation. This process plays a role in extracellular matrix remodeling. As a result, MRC2 deficiency in animal models has been correlated with increased fibrosis in organs including the lung, liver, and kidney. MRC2 is also upregulated in several types of cancer in humans, including a subset of breast cancers, prostate cancers, glioblastomas, acute myeloid leukemias (AML), and sarcomas. Increased MRC2 expression may contribute to increased tumor invasion and metastasis due to the degradation of the extracellular matrix in the tumor microenvironment (TME). Given its high expression in various cancer types and potential role in driving cancer progression, it will be useful to develop antibody-drug conjugates (ADCs), CAR (chimeric antigen receptor)-T cells, or other therapies targeting MRC2.